MXPA03006412A - Metodos para administrar analogos de epotilona para tratamiento de cancer. - Google Patents

Metodos para administrar analogos de epotilona para tratamiento de cancer.

Info

Publication number
MXPA03006412A
MXPA03006412A MXPA03006412A MXPA03006412A MXPA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
methods
epothilone analogs
administering epothilone
Prior art date
Application number
MXPA03006412A
Other languages
English (en)
Inventor
Rebanta Bandyopadhyay
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03006412A publication Critical patent/MXPA03006412A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA03006412A 2001-01-25 2002-01-22 Metodos para administrar analogos de epotilona para tratamiento de cancer. MXPA03006412A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000601P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (1)

Publication Number Publication Date
MXPA03006412A true MXPA03006412A (es) 2003-10-15

Family

ID=26950348

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006412A MXPA03006412A (es) 2001-01-25 2002-01-22 Metodos para administrar analogos de epotilona para tratamiento de cancer.

Country Status (10)

Country Link
JP (1) JP4633331B2 (es)
AU (1) AU2002245296B2 (es)
CA (1) CA2434526C (es)
HR (1) HRP20030677B1 (es)
IL (1) IL156578A0 (es)
MX (1) MXPA03006412A (es)
NO (1) NO335119B1 (es)
PL (1) PL207720B1 (es)
RU (1) RU2292202C2 (es)
WO (1) WO2002058700A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
AU2008200555C1 (en) * 2003-03-14 2011-12-15 Novartis Ag Treatment of proliferative diseases with epothilone derivatives and radiation
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
PT3002009T (pt) * 2007-06-01 2021-08-02 Wyeth Llc Tratamento de leucemia mielógena crónica resistente a imatinib tendo amutação 1457t>c no gene bcrabl utilizando o composto bosutinib
WO2009089138A1 (en) * 2008-01-04 2009-07-16 Bristol-Myers Squibb Company Oral administration of ixabepilone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
EP0977563B1 (en) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001510915A (ja) * 1997-07-18 2001-08-07 ヒューレット・パッカード・カンパニー デバイス間の情報受渡し用フォーマット
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
KR100669174B1 (ko) * 1998-02-05 2007-01-17 노파르티스 아게 유기화합물 함유 조성물
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
ES2291194T3 (es) * 1999-02-18 2008-03-01 Bayer Schering Pharma Aktiengesellschaft Derivados de 16-halogeno-epotilones, procedimiento acerca de su preparacion y su utilizacion farmaceutica.
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon

Also Published As

Publication number Publication date
JP4633331B2 (ja) 2011-02-16
RU2292202C2 (ru) 2007-01-27
PL373727A1 (en) 2005-09-05
NO20033341D0 (no) 2003-07-24
HRP20030677A2 (en) 2004-08-31
RU2003126170A (ru) 2005-02-27
CA2434526C (en) 2011-11-01
CA2434526A1 (en) 2002-08-01
JP2005503323A (ja) 2005-02-03
HRP20030677B1 (en) 2011-10-31
IL156578A0 (en) 2004-01-04
NO20033341L (no) 2003-09-04
WO2002058700A1 (en) 2002-08-01
AU2002245296B2 (en) 2006-12-21
PL207720B1 (pl) 2011-01-31
NO335119B1 (no) 2014-09-22

Similar Documents

Publication Publication Date Title
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
HK1116339A1 (en) Methods of administering epothilone analogs for the treatment of cancer
IL196301A0 (en) Medicament for the treatment of hapatitis c
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
IL164599A0 (en) Combination therapy for the treatment of cancer
HK1097410A1 (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer
EP1613308A4 (en) CANCER TREATMENT METHODS
EP1390029A4 (en) PHENYLINDOLES FOR THE TREATMENT OF HIV INFECTION
IL159887A0 (en) Combination therapy for the treatment of cancer
MXPA03007423A (es) Derivados de epotilona para tratamiento de tumores refractarios.
MXPA03007394A (es) Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
ZA200408767B (en) Immunoconjugates for the treatment of tumours
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
EP1545510A4 (en) SUBSTITUTED PHENYLINDOLE FOR THE TREATMENT OF HIV
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
AU2002304883A1 (en) Device for the treatment of tumours
AU2000263936A1 (en) Substance p analogs for the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration